Navigation Links
Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the,Annual Meeting of the Associated Professional Sleep Societies

ROCKVILLE, Md., June 08, 2007 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. announced today that Dr. Tom Roth, Director of the Henry Ford Sleep Disorders and Research Center in Detroit, MI, will deliver an oral presentation on recent Phase III clinical trial results for VEC-162, Vanda's balanced melatonin (MT1/MT2) receptor agonist, at SLEEP 2007, the 21st annual meeting of the Associated Professional Sleep Societies, (APSS).

The Vanda presentation will take place at the Convention Center in Minneapolis, MN on June 13 from 4:00pm - 4:15pm CDT, during the 2:45 - 4:45 pm session entitled, "O31: Pharmacotherapy of Insomnia."

Abstract ID 0773: "Melatonin Agonist VEC-162 Improves Sleep Onset and Maintenance in a Model of Transient Insomnia" (Roth, together with G. Birznieks; C.H. Scott P. Baroldi, M.D., Ph.D.; Mihael H. Polymeropoulos, M.D., Vanda Pharmaceuticals)

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness that is in a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

CONTACT: Steven A. Shallcross, Chief Financial Officer of VandaPharmaceuticals Inc., +1-240-599-4500,




Page: 1 2

Related medicine technology :

1. Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007 American Psychiatric Association Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:5/21/2008)...ong Group of Leading Cancer Centers ...f., May 21 /- Endocare, Inc...ompany focused on the,development of minimally inv...tional radiologists for tissue and tumor ablation,...vasive method of freezing cancerous tumors,to dest...
(Date:5/20/2008)...- Today at the,World Congre...led "New,Perspectives in Atrial Fibrillation Manag... Cardiology, St George,s University of London,hig...ENA clinical trial,results, as the way forward in ...most common form of cardiac arrhythmia., To view ...
(Date:5/20/2008)... Digestive Disease Week(R) 2008, NATICK, Mass. an...on,Scientific Corporation (NYSE: BSX ) today anno...patient registry documenting favorable safety,and ...isualization System,which offers extensive visual...istry were presented by Yang K. Chen, M.D., Divisi...
(Date:5/20/2008)...y at Digestive Disease Week -, CAMBRIDGE, Mass. a...wood Pharmaceuticals, Inc. (formerly Microbia, Inc...ay announced the presentation of data,from a Phase...tudy,assessing the safety and efficacy of linaclot...alysis of these data indicate that linaclotide met...
Breaking Medicine Technology:Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 2Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 3Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 2Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 3Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 4Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 2Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 3Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 4Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 6Association of Public Health Laboratories Applauds Signing of Newborn Screening Saves Lives Act 18422 1Association of Public Health Laboratories Applauds Signing of Newborn Screening Saves Lives Act 18422 2Scientists identify gatekeepers of breast cancer transition to invasive disease 18418 1Scientists identify gatekeepers of breast cancer transition to invasive disease 18418 2More efficient fuel cells thanks to a new catalyst 3185 1More efficient fuel cells thanks to a new catalyst 3185 2More efficient fuel cells thanks to a new catalyst 3185 3More efficient fuel cells thanks to a new catalyst 3185 4Protein May Trigger Colon Cancer 18411 1
...007 - Late breaking data,presented at the American... Sessions showed that, when used investigationally...combination with,metformin provided significant gl...d over 54 weeks in patients with type 2,diabetes. ...resented also showed that JANUVIA significantly im...
...E)--June 25, 2007--Gilead,Sciences, Inc. (Nasdaq:G...linical trial evaluating the company,s once-daily,...rate or tenofovir,DF) 300 mg as a potential treatm... met its primary efficacy endpoint. The data show,...daily antiviral,drug Hepsera(R) (adefovir dipivoxi...
Other Medicine Technology:Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 2Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 3Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 4Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 7Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 8Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 9Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 10Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 11Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 12Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 13Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 14Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 15Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 16Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 17Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 18Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 19Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 20Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 21Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 22Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 23Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 24Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 25Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 26Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 27Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 28Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 29Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 30Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 31Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 32Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
...eille Guiliano’s bestseller ‘French Women Don’t Ge...nment figures, 5.9 million of France's 63.4 millio.... The figures have got the French government scra...e ways to come back to the former image of the sve...
...amin supplements and low fat dairy products in Bri...inding which was published// in The Journal of the...finding consumption of vitamin pills for a prolong...ality rate by 5% and low fat dairy may hamper the ...
...tain’s pay deals given by pay review bodies of the... millions of public sector workers across the coun...specially negative, in the medical sector. Healt... announced that GPs or family doctors will get a z...
Busting the Exam Blues
Other Medicine News:Health News:UK’s Health Services Totterin 2Health News:Busting the Exam Blues 2Health News:Busting the Exam Blues 3Health News:Busting the Exam Blues 4
...r System combines precision with ease of operation...ns. The pneumatic motor powered system developed f...rocedures includes a drill, sagittal saw (extended...th available), reciprocating saw (extended length ...
Elmed Retract - Robot an single arm instrument, with extra long (10") horizontal extension for improved cephalad and anterior retraction. Retract - Robot (Retractor system) was designed to assist sur
Fortitude as a unique complement to the spinal concepts family of products.
As a unique complement to the spinal concepts family of products.
Medicine Products: